See more : Energy Transition Minerals Ltd (GDLNF) Income Statement Analysis – Financial Results
Complete financial analysis of Greenwich LifeSciences, Inc. (GLSI) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Greenwich LifeSciences, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- New Global Energy, Inc. (NGEY) Income Statement Analysis – Financial Results
- Hopium SA (ALHPI.PA) Income Statement Analysis – Financial Results
- Coforge Limited (COFORGE.BO) Income Statement Analysis – Financial Results
- Netgem SA (ALNTG.PA) Income Statement Analysis – Financial Results
- SEBinvest AKL Nordamerika Aktie (SEINAASRII.CO) Income Statement Analysis – Financial Results
Greenwich LifeSciences, Inc. (GLSI)
About Greenwich LifeSciences, Inc.
Greenwich LifeSciences, Inc., a clinical stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is the GP2, an immunotherapy, which has completed Phase IIb clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery. The company was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. Greenwich LifeSciences, Inc. was incorporated in 2006 and is headquartered in Stafford, Texas.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 3.61K | 3.61K | 3.61K | 3.61K | 3.61K | 3.61K | 3.61K |
| Gross Profit | -3.61K | -3.61K | -3.61K | -3.61K | -3.61K | -3.61K | -3.61K |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 7.70M | 6.48M | 3.56M | 1.06M | 2.61M | 1.27M | 1.22M |
| General & Administrative | 1.63M | 1.56M | 1.04M | 806.19K | 818.89K | 419.64K | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 1.63M | 1.56M | 1.04M | 806.19K | 818.89K | 419.64K | 346.81K |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 9.33M | 8.04M | 4.60M | 1.86M | 3.43M | 1.69M | 1.57M |
| Cost & Expenses | 9.33M | 8.04M | 4.60M | 1.86M | 3.43M | 1.69M | 1.57M |
| Interest Income | 436.06K | 215.02K | 27.37K | 832.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 3.61K | 3.61K | 3.61K | 3.61K | 3.61K | 3.61K | 3.61K |
| EBITDA | -9.32M | -8.04M | -4.59M | -1.86M | -3.42M | -1.69M | -1.57M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -9.33M | -8.04M | -4.60M | -1.86M | -3.43M | -1.69M | -1.57M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 436.06K | 215.02K | 27.37K | 832.00 | 0.00 | 0.00 | 0.00 |
| Income Before Tax | -8.89M | -7.83M | -4.57M | -1.86M | -3.43M | -1.69M | -1.57M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -215.02K | -27.37K | -832.00 | 3.00 | -157.53K | 3.00 |
| Net Income | -8.89M | -7.61M | -4.54M | -1.86M | -3.43M | -1.69M | -1.57M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.69 | -0.59 | -0.35 | -0.15 | -0.29 | -0.14 | -0.13 |
| EPS Diluted | -0.69 | -0.59 | -0.35 | -0.15 | -0.29 | -0.14 | -0.13 |
| Weighted Avg Shares Out | 12.85M | 12.91M | 12.94M | 12.70M | 11.74M | 11.97M | 11.74M |
| Weighted Avg Shares Out (Dil) | 12.85M | 12.91M | 12.94M | 12.70M | 11.74M | 11.97M | 11.74M |
Greenwich LifeSciences Could See Another Spike in Stock in Early April
On December 8, 2020, Greenwich LifeSciences (NASDAQ: GLSI) share price closed at $5.20 per share. Greenwich LifeSciences published its 5-year breast cancer data from a Phase IIb trial at the San Antonio Breast Cancer Symposium conference on December 9, which...
Exclusive: Greenwich LifeSciences CEO Calls Stock's Meteoric Rise 'Very Emotional'
Greenwich LifeSciences, Inc. (NASDAQ: GLSI) is a biopharmaceutical company that is developing GP2, an immunotherapy to prevent breast cancer recurrences in certain patients. The stock skyrocketed nearly 3,000% in a single day in December after a Phase 2b trial suggested the therapy can...
Greenwich LifeSciences Updates 2021 Timeline & Announces Two Upcoming Presentations at the American Association for Cancer Research Annual Meeting
STAFFORD, Texas--(BUSINESS WIRE)--Greenwich LifeSciences Updates 2021 Timeline & Announces Two Upcoming Presentations at the American Association for Cancer Research Annual Meeting
Greenwich LifeSciences CEO to be Interviewed Live on Benzinga's Power Hour
STAFFORD, Texas--(BUSINESS WIRE)--Greenwich LifeSciences CEO to be Interviewed Live on Benzinga's Power Hour - Interview will air on Thursday, March 11, 2021 at 12:30 pm EST
Why Greenwich LifeSciences Stock Skyrocketed Today
Investors cheered an important new hire.
GLSI Stock: Why Greenwich LifeSciences Is Skyrocketing Today
GLSI stock is skyrocketing again on Monday after the company appointed Dr. Jaye Thompson to run its Phase 3 clinical trials. The post GLSI Stock: Why Greenwich LifeSciences Is Skyrocketing Today appeared first on InvestorPlace.
GLSI Stock Price Increased Over 130% Intraday: Why It Happened
The stock price of Greenwich Lifesciences Inc (NASDAQ: GLSI) increased by over 130% during intraday trading. This is why it happened.
Greenwich LifeSciences Hires Industry Expert, Dr. Jaye Thompson, to Manage Phase III Clinical Trial for Recurring Breast Cancer
STAFFORD, Texas--(BUSINESS WIRE)--Greenwich LifeSciences Hires Industry Expert, Dr. Jaye Thompson, to Manage Phase III Clinical Trial for Recurring Breast Cancer
Greenwich LifeSciences Announces Acceptance of Two Abstracts at Upcoming Major Cancer Conference
STAFFORD, Texas--(BUSINESS WIRE)--Greenwich LifeSciences Announces Acceptance of Two Abstracts at Upcoming Major Cancer Conference
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Greenwich LifeSciences, Inc.- GLSI
New York, New York--(Newsfile Corp. - February 2, 2021) - Levi & Korsinsky announces it has commenced an investigation of Greenwich LifeSciences, Inc. (NASDAQ: GLSI) concerning possible breaches of fiduciary duty. To obtain additional information, go to:https://www.zlk.com/compensation2/greenwich-lifesciences-inc-information-request-formor contact Joseph E....
Source: https://incomestatements.info
Category: Stock Reports